UK-based Celsis International says that its first-half 2008 pretax profit jumped 17.8% year-on-year to $5.0 million, thanks to the performance of its rapid detection and in vitro technology businesses.
The firm, which provides services and products to the life science industry, said that group revenue increased 3.5% to $27.2 million during the period, as earnings before interest taxes depreciation and amortization jumped 11.5% to $6.5 million, while profit before tax adjusted for amortization of intangible assets increased 16.3% to $5.3 million. Earnings per share rose 14.1% to $0.15.
Despite its solid results, on the morning of the announcement, November 12, shares fell 7.4% to 143.5 pence on the London Stock Exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze